{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:46:20Z","timestamp":1786373180959,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>The effects of recombinant human growth hormone on renal osteodystrophy are unknown; thus, the effects of growth hormone (GH) on bone histomorphometry were assessed in pediatric patients with ESRD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>Thirty-three patients who underwent bone biopsy between July 1994 and May 1999 were randomly assigned to therapy with or without GH. Patients were stratified by bone formation rate; all patients with high bone turnover received intraperitoneal calcitriol. Serum biochemical values were obtained monthly, and bone biopsy was repeated after 8 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Median patient age was 11.7 years (interquartile range [IQR], 7.6, 14.1 years); 45% of patients were male, and 52% were prepubertal. Median dialysis duration was 0.4 (IQR, 0.3, 0.8) year. Bone formation rate per bone surface increased from 15.0 (9.6, 21.8) to 154.6 (23.7, 174.3) \u03bcm\n                      <jats:sup>2<\/jats:sup>\n                      \/\u03bcm\n                      <jats:sup>3<\/jats:sup>\n                      per year (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.05) in patients with low bone turnover treated with GH, decreased from 103.3 (57.0, 173.4) to 60.3 (20.3, 13.7) \u03bcm\n                      <jats:sup>2<\/jats:sup>\n                      \/\u03bcm\n                      <jats:sup>3<\/jats:sup>\n                      per year in patients with high bone turnover receiving standard therapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.03), and was unchanged in the other two groups. Bone formation rates were higher with GH, irrespective of underlying bone histologic features (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.05). Parathyroid hormone did not differ between groups. GH therapy resulted in greater increases in height SD scores (estimated mean difference in change \u00b1 SD, 0.324\u00b10.076;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), irrespective of underlying bone histologic features.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GH therapy improves height in pediatric dialysis patients, irrespective of underlying bone histologic features. Bone formation rates are higher in GH recipients, and GH therapy alters the relationship between circulating parathyroid hormone values and bone turnover.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.00330112","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T23:53:49Z","timestamp":1365119629000},"page":"824-832","source":"Crossref","is-referenced-by-count":31,"title":["The Skeletal Consequences of Growth Hormone Therapy in Dialyzed Children"],"prefix":"10.2215","volume":"8","author":[{"given":"Justine","family":"Bacchetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Wesseling-Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Kuizon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata C.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-19-20230811","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJM200009283431304","article-title":"Effect of growth hormone treatment on the adult height of children with chronic renal failure.","volume":"343","author":"Haffner","year":"2000","journal-title":"N Engl J Med"},{"key":"R4-19-20230811","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0140-6736(91)90604-N","article-title":"Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure.","volume":"338","author":"Hokken-Koelega","year":"1991","journal-title":"Lancet"},{"key":"R5-19-20230811","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1210\/jc.2007-2302","article-title":"Factors predicting the near-final height in growth hormone-treated children and adolescents with chronic kidney disease.","volume":"93","author":"Nissel","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-19-20230811","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000185098","article-title":"Changes in bone mineral density, growth velocity and renal function of prepubertal uremic children during growth hormone treatment.","volume":"46","author":"Lanes","year":"1996","journal-title":"Horm Res"},{"key":"R7-19-20230811","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2265.1998.00593.x","article-title":"Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment.","volume":"49","author":"Boot","year":"1998","journal-title":"Clin Endocrinol (Oxf"},{"key":"R8-19-20230811","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1440-1797.2004.00318.x","article-title":"Long-term recombinant human growth hormone use in Australian children with renal disease.","volume":"9","author":"Crompton","year":"2004","journal-title":"Nephrology (Carlton"},{"key":"R9-19-20230811","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5414\/CNP74097","article-title":"Treatment of growth failure with growth hormone in children with chronic kidney disease: An open-label long-term study.","volume":"74","author":"M\u00fcller-Wiefel","year":"2010","journal-title":"Clin Nephrol"},{"key":"R10-19-20230811","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","article-title":"Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD.","volume":"53","author":"Kuizon","year":"1998","journal-title":"Kidney Int"},{"key":"R11-19-20230811","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJM197802022980503","article-title":"Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy.","volume":"298","author":"Chesney","year":"1978","journal-title":"N Engl J Med"},{"key":"R12-19-20230811","first-page":"327","article-title":"Acquisition of bone mass in normal individuals and in patients with growth hormone deficiency.","volume":"16","author":"Baroncelli","year":"2003","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R13-19-20230811","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1210\/jc.2003-030761","article-title":"Adults with partial growth hormone deficiency have an adverse body composition.","volume":"89","author":"Murray","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R14-19-20230811","first-page":"1919","article-title":"Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.","volume":"84","author":"Colao","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R15-19-20230811","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/ki.1995.335","article-title":"Growth hormone and calcitriol as modifiers of bone formation in renal osteodystrophy.","volume":"48","author":"Salusky","year":"1995","journal-title":"Kidney Int"},{"key":"R16-19-20230811","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.5650100104","article-title":"Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids.","volume":"10","author":"Sanchez","year":"1995","journal-title":"J Bone Miner Res"},{"key":"R17-19-20230811","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.2215\/CJN.00460107","article-title":"Technical approach to iliac crest biopsy.","volume":"3","author":"Hernandez","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R18-19-20230811","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1046\/j.1523-1755.1998.00866.x","article-title":"Bone disease in children and adolescents undergoing successful renal transplantation.","volume":"53","author":"Sanchez","year":"1998","journal-title":"Kidney Int"},{"key":"R19-19-20230811","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jbmr.5650020617","article-title":"Bone histomorphometry: Standardization of nomenclature, symbols, and units.","volume":"2","author":"Parfitt","year":"1987","journal-title":"J Bone Miner Res"},{"key":"R20-19-20230811","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"R21-19-20230811","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ajcn\/38.4.599","article-title":"Nutritional status of children undergoing continuous ambulatory peritoneal dialysis.","volume":"38","author":"Salusky","year":"1983","journal-title":"Am J Clin Nutr"},{"key":"R23-19-20230811","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00467-005-2082-7","article-title":"Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.","volume":"21","author":"Klaus","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"R24-19-20230811","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/clinchem\/44.4.805","article-title":"A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples.","volume":"44","author":"Lepage","year":"1998","journal-title":"Clin Chem"},{"key":"R25-19-20230811","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1994.380","article-title":"Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.","volume":"46","author":"Goodman","year":"1994","journal-title":"Kidney Int"},{"key":"R26-19-20230811","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"key":"R27-19-20230811","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jbmr.265","article-title":"Growth hormone mediates pubertal skeletal development independent of hepatic IGF-1 production.","volume":"26","author":"Courtland","year":"2011","journal-title":"J Bone Miner Res"},{"key":"R28-19-20230811","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0272-6386(12)80566-X","article-title":"Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients.","volume":"16","author":"Salusky","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"R29-19-20230811","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00467-009-1143-8","article-title":"Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols.","volume":"24","author":"Wesseling-Perry","year":"2009","journal-title":"Pediatr Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201305000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:43:13Z","timestamp":1786369393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201305000-00019"}},"subtitle":["A Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.00330112","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006415.793477449","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.718006415.793477052","asserted-by":"object"}]},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}